secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0000950170-25-077373
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026
--------------------------------------------------------------------------------

- Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.
- LUCIA trial 60% randomized; enrollment completion expected Q3 2025.
- Topline 56-week LUGANO data mid-2026; LUCIA data in H2 2026.
- Phase 3 trials are randomized, double-masked, non-inferiority vs. aflibercept; DURAVYU dosed every 6 months.
- DURAVYU is sustained-delivery vorolanib (TKI); potential first sustained-release TKI for wet AMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/0000950170-25-077373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-20250527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-077373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer